agilon health(US:AGL) Businesswire·2026-01-14 17:00Core Viewpoint - A securities fraud class action lawsuit has been filed against agilon health, inc. on behalf of investors who acquired its securities during the specified Class Period, following significant stock price decline due to leadership changes and missed financial estimates [1][2]. Group 1: Company Developments - On August 4, 2025, agilon announced the departure of its President, CEO, and Director, which was classified as a termination without cause under his employment agreement [2]. - The company released its second quarter 2025 financial results on the same day, which missed estimates and led to the suspension of its 2025 guidance due to leadership changes and ongoing market uncertainties [2]. Group 2: Stock Performance - Following the announcement of leadership changes and poor financial results, agilon's stock price dropped by $0.93, or 51.5%, closing at $0.88 per share on August 5, 2025 [2]. Group 3: Allegations in the Lawsuit - The lawsuit alleges that during the Class Period, agilon's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [3]. - Specific allegations include that management issued guidance for 2025 that was known or should have been known to be unachievable due to industry headwinds, and that they overstated the financial impact of strategic actions taken to reduce risk [3].